MoonLake Immunotherapeutics(US:MLTX) Newsfile·2025-11-30 03:14Core Viewpoint - Rosen Law Firm is reminding investors of MoonLake Immunotherapeutics to secure counsel before the December 15, 2025 lead plaintiff deadline for a securities class action related to stock purchases made between March 10, 2024, and September 29, 2025 [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone, and has consistently ranked in the top 4 for securities class action settlements since 2013 [4]. Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, failing to disclose material facts about the product's clinical benefits [5]. - Specific claims include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure would not provide superior clinical benefits or efficacy [5].